

Mengchang Wang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2284469/publications.pdf>

Version: 2024-02-01

8
papers

56
citations

1937685

4
h-index

1720034

7
g-index

8
all docs

8
docs citations

8
times ranked

135
citing authors

| # | ARTICLE | IF | CITATIONS |
|---|--|-----|-----------|
| 1 | BCL2-BH4 antagonist BDA-366 suppresses human myeloma growth. <i>Oncotarget</i> , 2016, 7, 27753-27763. | 1.8 | 19 |
| 2 | Norepinephrineâ€CREB1â€miRâ€373 axis promotes progression of colon cancer. <i>Molecular Oncology</i> , 2020, 14, 1059-1073. | 4.6 | 16 |
| 3 | Dendritic cell-activated cytokine-induced killer cell-mediated immunotherapy is safe and effective for cancer patients >65 years old. <i>Oncology Letters</i> , 2016, 12, 5205-5210. | 1.8 | 7 |
| 4 | Gene expression profile of multiple myeloma cell line treated by arsenic trioxide. <i>Journal of Huazhong University of Science and Technology [Medical Sciences]</i> , 2007, 27, 646-649. | 1.0 | 6 |
| 5 | As₄S₄ Exhibits Good Killing Effect on Multiple Myeloma Cells Via Repressing SOCS1 Methylation-Mediated JAK2/STAT3 Signaling Pathway. <i>Technology in Cancer Research and Treatment</i> , 2019, 18, 153303381989680. | 1.9 | 4 |
| 6 | Silence of MCL-1 upstream signaling by shRNA abrogates multiple myeloma growth. <i>Experimental Hematology and Oncology</i> , 2014, 3, 27. | 5.0 | 3 |
| 7 | Arsenic Trioxide Combined with VCMP or VAD Chemotherapy in Patients with Refractory or Relapsed Multiple Myeloma in a Single Institution of China. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2014, 30, 259-264. | 0.6 | 1 |
| 8 | Small Molecule Bda-366 As a Bcl2-BH4 Antagonist for Multiple Myeloma Therapy. <i>Blood</i> , 2015, 126, 2049-2049. | 1.4 | 0 |